Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Cytosine deaminase as a negative selective marker for Arabidopsis.

Perera RJ, Linard CG, Signer ER.

Plant Mol Biol. 1993 Nov;23(4):793-9. Erratum in: Plant Mol Biol 1994 Mar;24(5):832.

PMID:
8251632
2.

A conditional negative selection for Arabidopsis expressing a bacterial cytosine deaminase gene.

Kobayashi T, Hisajima S, Stougaard J, Ichikawa H.

Jpn J Genet. 1995 Jun;70(3):409-22.

3.
4.
6.

In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer.

Evoy D, Hirschowitz EA, Naama HA, Li XK, Crystal RG, Daly JM, Lieberman MD.

J Surg Res. 1997 Apr;69(1):226-31.

PMID:
9202675
7.

Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.

Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB.

Blood. 1998 Jul 15;92(2):672-82.

8.

Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine.

Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G.

FEMS Microbiol Lett. 1998 Oct 1;167(1):41-9.

10.

Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates.

Senter PD, Su PC, Katsuragi T, Sakai T, Cosand WL, Hellström I, Hellström KE.

Bioconjug Chem. 1991 Nov-Dec;2(6):447-51.

PMID:
1805942
11.
12.

Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.

Ge K, Xu L, Zheng Z, Xu D, Sun L, Liu X.

Int J Cancer. 1997 May 16;71(4):675-9.

14.

Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect.

Pierrefite-Carle V, Baqué P, Gavelli A, Mala M, Chazal M, Gugenheim J, Bourgeon A, Milano G, Staccini P, Rossi B.

J Natl Cancer Inst. 1999 Dec 1;91(23):2014-9.

PMID:
10580026
15.

Cytosine deaminase gene as a positive selection marker.

Wei K, Huber BE.

J Biol Chem. 1996 Feb 16;271(7):3812-6.

16.

Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.

Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, Brown JM.

Gene Ther. 1996 Feb;3(2):173-8. Erratum in: Gene Ther 1996 Aug;3(8):741.

PMID:
8867865
18.

Regression of experimental liver tumor after distant intra-hepatic injection of cytosine deaminase-expressing tumor cells and 5-fluorocytosine treatment.

Pierrefite-Carle V, Baque P, Gavelli A, Benchimol D, Bourgeon A, Milano G, Saint-Paul MC, Rossi B.

Int J Mol Med. 2000 Mar;5(3):275-8.

PMID:
10677568
19.

In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.

Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA.

Cancer Res. 1993 Oct 1;53(19):4619-26.

PMID:
8402637
20.

In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene.

Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H, Tamaoki T, Omata M.

Cancer Res. 1997 Feb 1;57(3):461-5.

Supplemental Content

Support Center